Anaphylaxis following quadrivalent human papillomavirus vaccination.
about
Human papillomavirus vaccine risk and realityImportance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccinesSafety of human papillomavirus vaccines: a review.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccineHuman papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study.Human papillomavirus vaccination for boysHPV vaccine for cancer and wart prevention.Evidence-based clinical guidelines for immigrants and refugees.Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerRisk of anaphylaxis after vaccination in children and adultsVaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018Review of Gardasil.Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: updated review.Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.Human papillomavirus vaccines: current status and future prospects.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.Allergic reactions to vaccines.Managing a child with possible allergy to vaccine.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Vaccination and allergy: EAACI position paper, practical aspects.The human papillomavirus vaccine and risk of anaphylaxis.Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.Le vaccin contre le virus du papillome humain : risques et réalités.
P2860
Q24655937-0234D343-F034-41B3-9808-8B01F7C878C3Q30382146-1A9F7996-1CD3-425A-AF10-02F83B027780Q33162724-DD02BF47-AF3B-4E40-8EF2-51F5E12E3299Q33451335-6FEA5394-87B2-46D5-8D6F-63DBDA1AF74CQ34029941-46D15F5B-C8D7-493A-B418-E1335E826ADEQ34272071-0644C193-F463-484E-8F14-6DDB5FDD790FQ34462627-C3574057-7BCE-4203-8580-588E097213BFQ34994792-C7B6B3F1-C418-48AE-802E-D6F770DFE007Q34994797-3708EF0C-3967-48E8-937C-D8A2587FDE1DQ35201293-26D8BB65-0160-4D7D-836A-D8E3BFEC088DQ35258843-DCCE39EA-B8CA-4FCD-9240-311F0A866979Q36665226-BAC21112-BABE-4D58-994F-92B040D4BE74Q36743080-46F46538-54B6-42BD-80BF-A97CE80A6E1CQ36949778-DCE6C026-9EB8-4433-BE84-8849CDC8EE25Q37251638-64974A29-AC5E-46AE-9BDD-9A0027280442Q37702739-75001906-1184-4E69-8F79-A3F644262389Q37762242-0BC4E477-5CC7-447A-87D9-BE938EABF24AQ37818140-072888E1-D01F-441B-A6C5-F5F42DF2FA62Q37912228-904C363D-00E2-46A6-97C4-4A65B0654EC0Q38125517-A66104C4-7B7B-4513-969C-98B113308C75Q38153078-7EE82685-3BA5-4080-82BB-A937663BF48EQ38229304-FD9E66C1-9B1C-4382-8E02-38C97F0C82DDQ40105652-560BCCEB-2305-4BCF-B7E9-B867A5717429Q42424067-20D0E027-BC19-4F83-A590-4F3FDC359107Q45382040-0F6F4AC1-6725-4308-B518-ED25C86F4919Q46081872-4DFBC133-EEBB-49D8-9269-984072EB0B4B
P2860
Anaphylaxis following quadrivalent human papillomavirus vaccination.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Anaphylaxis following quadrivalent human papillomavirus vaccination.
@en
type
label
Anaphylaxis following quadrivalent human papillomavirus vaccination.
@en
prefLabel
Anaphylaxis following quadrivalent human papillomavirus vaccination.
@en
P2093
P2860
P356
P1476
Anaphylaxis following quadrivalent human papillomavirus vaccination.
@en
P2093
Andrew S Kemp
Julia M L Brotherton
Margaret A Burgess
Mike S Gold
New South Wales Health HPV Adverse Events Panel
Peter B McIntyre
Sue Campbell-Lloyd
P2860
P304
P356
10.1503/CMAJ.080916
P407
P577
2008-09-01T00:00:00Z